Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

@article{Gilbert2013DosedenseTF,
  title={Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.},
  author={M D Richard Gilbert and Meihua Wang and Kenneth D. Aldape and Roger Stupp Stupp and Monika E Hegi and Kurt A. Jaeckle and Terri S. Armstrong and Jeffrey Scott Wefel and M. C. Won and Deborah T. Blumenthal and A. O. Mahajan and C J Schultz and Sara Catherine Erridge and Brigitta G. Baumert and Kristen Hopkins and Tzahala Tzuk-Shina and P D Brown and Arnab Chakravarti and Walter J. Curran and Minesh P Mehta},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2013},
  volume={31 32},
  pages={
          4085-91
        }
}
PURPOSE Radiotherapy with concomitant and adjuvant temozolomide is the standard of care for newly diagnosed glioblastoma (GBM). O(6)-methylguanine-DNA methyltransferase (MGMT) methylation status may be an important determinant of treatment response. Dose-dense (DD) temozolomide results in prolonged depletion of MGMT in blood mononuclear cells and possibly in tumor. This trial tested whether DD temozolomide improves overall survival (OS) or progression-free survival (PFS) in patients with newly… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 239 CITATIONS

Current Standards of Care in Glioblastoma Therapy

VIEW 19 EXCERPTS
CITES METHODS, BACKGROUND & RESULTS
HIGHLY INFLUENCED

Effect of Bevacizumab Plus Temozolomide-Radiotherapy for Newly Diagnosed Glioblastoma with Different MGMT Methylation Status: A Meta-Analysis of Clinical Trials

  • Medical science monitor : international medical journal of experimental and clinical research
  • 2016
VIEW 4 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Case-Based Review: newly diagnosed glioblastoma

VIEW 3 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

The future of high-grade glioma: Where we are and where are we going

  • Surgical neurology international
  • 2015
VIEW 14 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

From imaging to biology of glioblastoma: new clinical oncology perspectives to the problem of local recurrence.

  • Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • 2018
VIEW 9 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2018
VIEW 11 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials.

  • Journal of cellular physiology
  • 2018
VIEW 3 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2012
2019

CITATION STATISTICS

  • 18 Highly Influenced Citations

  • Averaged 42 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 21 REFERENCES

Pseudoprogression following chemoradiotherapy for glioblastoma multiforme.

  • The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • 2010
VIEW 1 EXCERPT

Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
VIEW 1 EXCERPT

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
VIEW 1 EXCERPT

Targeted modulation of MGMT: clinical implications.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2006
VIEW 2 EXCERPTS

Similar Papers

Loading similar papers…